Orion profit falls as Parkinson's drug patents expire
HELSINKI, April 23
HELSINKI, April 23 (Reuters) - Finnish drug maker Orion reported a fall in first-quarter profit, in line with expectations, due to the expiration of its patents for Parkinson's drugs.
Orion's quarterly operating profit fell 6 percent from a year earlier to 74 million euros ($96 million), matching the average forecast of analysts in a Reuters poll.
The company repeated it expects a slight fall in full-year 2013 operating profit, and shares in the company fell 0.8 percent to 20.20 euros. ($1 = 0.7674 euros) (Reporting By Jussi Rosendahl)
- Special Report: Thailand secretly supplies Myanmar refugees to trafficking rings |
- The 10 Most Corrupt and Least Corrupt Countries in the World
- NSA gathers data on cellphone locations globally: report
- China's airspace zone has caused apprehension: Biden |
- JPMorgan warns 465,000 card users on data loss after cyber attack